Navigating the new normal: ​Debating the place of high-efficacy vs escalation treatment approaches in MS

Meeting date: 18 November 2020



Chair: Professor Nikos Evangelou, Associate Professor of Neurology, University of Nottingham
For: Dr Waqar Rashid,​ Consultant Neurologist, St George’s University Hospital​
Against: Dr David Paling, ​Consultant Neurologist, Sheffield Teaching Hospitals
Considering the latest scientific evidence, clinical experiences and our changing world, esteemed MS experts, Dr Waqar Rashid and Dr David Paling, debate whether in the new normal, treatment with disease-modifying therapies should be initiated using high-efficacy treatments in the majority of MS patients​. 
Following the debate, Professor Nikos Evangelou leads an open educational discussion to explore the challenging decision process in managing MS treatment in today’s new normal and beyond. 
This meeting was organised and funded by Novartis Pharmaceuticals UK Ltd. The views expressed are those of the speakers and do not necessarily reflect those of Novartis.  

Rate this content: 
Average: 5 (1 vote)
UK | August 2021 | 138864

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com